This trial assessed adding an infusion of the drug nivolumab—or a placebo—to the pre-surgery phase and then assessing how patients respond overall, and the practice changing results have been ...

Researchers have discovered how a cell surface protein called Aplp1 can play a role in spreading material responsible for ...

Dana-Farber Cancer Institute researchers will present important research studies during the 2025 ASCO Genitourinary (GU) ...

The immunotherapy used in the trial was nivolumab ( Opdivo ), a drug delivered intravenously that works by disabling a ...

significantly slowed disease progression versus a single drug, according to a randomized study. Median progression-free survival (PFS) had yet to be reached with nivolumab (Opdivo) plus ipilimumab ...

Three trials presented at ASCO GI 2025 will change practice and improve the treatment of colorectal cancer, according to experts.

During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed how data from the CheckMate-067 and RELATIVITY-047 ...

Patients may require life-long monitoring and a collaborative engagement with subspecialists to keep well in the long -term,” ...

Adding an immunotherapy drug to the chemotherapy that patients receive ahead of surgery can dramatically improve breast cancer cure rates.